CROI 2013: Researchers Look at Neurological Complications among People with HIV
- Details
- Category: HIV-Related Conditions
- Published on Monday, 25 March 2013 00:00
- Written by Matt Sharp
Data from a small, yet well-designed trial to evaluate whether particular antiretroviral therapy (ART) regimens penetrate the central nervous system (CNS) and enhance neurocognitive performance were among several interesting findings regarding neurological complications among people with HIV presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta. Another study looked at similarities between Alzheimer's disease and neurocognitive impairment in people with HIV.
CROI 2013: Transmitted Antiretroviral Drug Resistance Holds Steady at 16% [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 25 March 2013 00:00
- Written by Gregory Fowler
Approximately 1 in 6 analyzed HIV sequences showed evidence of antiretroviral drug resistance, with NNRTIs being particularly vulnerable, according to a CDC analysis presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Maraviroc Does Not Prevent Immune Reconstitution Syndrome [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The CCR5 co-receptor blocker maraviroc (Selzentry) did not reduce the risk of developing immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART), according to study findings presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
Long-awaited results from the VOICE trial of post-exposure prophylaxis (PrEP) for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine (the drugs in Truvada) could lower the risk of HIV acquisition.
CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]
- Details
- Category: HCV Treatment
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.
[Produced in collaboration with IFARA]
In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.
More Articles...
- CROI 2013: Statins for People with HIV -- How Sweet Is It?
- CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]
- CROI 2013: HIV and Aging -- Are People with HIV at Greater Risk for Heart Disease and Cancer? [VIDEO]
- New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women
Web Design and Development by